PDCD1 and neoplasm: Therefore, we hypothesized that anti-PD-1 antibodies would be capable of effectively delivering IL-12 mutants to tumor-infiltrating PD-1+CD8+T cells instead of peripheral NK or T cells for greater antitumor efficacy while circumventing NK-mediated toxicity.